Goldman lifts target for Argenx stock to EUR 959.00

Published on 10/16/2026 at 15:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due on October 22, 2026. Argenx stock costs EUR 748.60 on October 16, 2026, minus 0.51 percent versus the Tradegate close.

Targets and dates shape the view

Goldman Sachs raised its Argenx target from EUR 954.00 to EUR 959.00 in a report dated October 15, 2026.
Argenx is scheduled to report third-quarter results on October 22, 2026.
Argenx stock costs EUR 748.60 at Lang & Schwarz on October 16, 2026 at 3:04 p.m. CEST, minus 0.51 percent versus the Tradegate close of October 15, 2026.
Argenx has a price earnings ratio of 32.23 and a market capitalization of USD 52.3 billion.

Bauhaus-Grafikposter: IgG-Antikörper als geometrisches Y-Symbol in Primärfarben Rot Blau Gelb Schwarz auf weißem Grund, konstruktivistischer Stil der 1920er Jahre — Argenx NL0010832176 IgG-Antikörper als Y-förmiges Bauhaus-Poster in roten blauen und gelben Primärfarben, Illustration mit AI erstellt.

Goldman Sachs raised its Argenx target from EUR 954.00 to EUR 959.00 in a report dated October 15, 2026, according to T-Online. The target is 28.11 percent above the EUR 748.60 price at Lang & Schwarz. Argenx was trading at EUR 748.60 at Lang & Schwarz on October 16, 2026 at 3:04 p.m. CEST, minus 0.51 percent versus the Tradegate close of October 15, 2026.

Results arrive on October 22

Argenx is scheduled to report its third-quarter 2026 results on October 22, 2026. Markets Insider listed the date alongside its October 14, 2026 report on analyst expectations. For investors, the result date gives the next fixed checkpoint for revenue, earnings and Vyvgart performance.

Price sits below the analyst target

The Goldman target implies 28.11 percent upside from the Lang & Schwarz price, using EUR figures for both values. The current quote is between a EUR 748.40 bid and a EUR 748.80 ask at the 3:04 p.m. CEST timestamp. The price move versus the Tradegate close was minus 0.51 percent, keeping the daily change below the level at which a directional headline would be appropriate.

Valuation and market comparison

argenx has a market capitalization of USD 52.3 billion and a price earnings ratio of 32.23, based on the latest finance snapshot dated October 15, 2026. Regeneron Pharmaceuticals traded at USD 796.34 on October 15, 2026, up 2.31 percent, with a price earnings ratio of 19.70 and a market capitalization of USD 82.0 billion. UCB traded at EUR 202.90 on October 16, 2026, down 1.50 percent, with a price earnings ratio of 17.58 and a market capitalization of EUR 38.7 billion.

Comparison with peers

argenx (Euronext Brussels, EUR): minus 0.51 percent, price earnings ratio 32.23, market capitalization USD 52.3 billion
Regeneron (Nasdaq, USD): plus 2.31 percent, price earnings ratio 19.70, market capitalization USD 82.0 billion
UCB (Euronext Brussels, EUR): minus 1.50 percent, price earnings ratio 17.58, market capitalization EUR 38.7 billion

Target and reporting date

The higher Goldman target and the October 22 reporting date give the stock two distinct reference points. The target is a dated analyst view, while the results release will provide the next company-specific operating evidence.

Trading stays near EUR 749

Argenx was trading at EUR 748.60 at Lang & Schwarz on October 16, 2026 at 3:04 p.m. CEST, minus 0.51 percent versus the Tradegate close of October 15, 2026 (EUR 752.40). The further course of trading is shown by the continuously updated real-time quote of Argenx stock.